Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma

Chen, L. N., & Carvajal, R. D. (2022). Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma. Expert Review of Anticancer Therapy, 22(10), 1017–1027. https://doi.org/10.1080/14737140.2022.2124971
Authors:
Lanyi Nora Chen
Richard D Carvajal
Affiliated Authors:
Lanyi Nora Chen
Richard D Carvajal
Columbia Affiliation:
Subjects:
Immunoconjugates (MeSH)
Uveal Neoplasms (MeSH)
Author Keywords:
gp100
immune-mobilizing monoclonal t cell receptor against cancer
immunotherapy
tebentafusp
uveal melanoma
elink
Publication Type:
Article
Unique ID:
10.1080/14737140.2022.2124971
PMID:
36102132
DOI:
10.1080/14737140.2022.2124971
Journal:
Expert Review of Anticancer Therapy
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Web of Science Record

Record Created: